Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genes May Predict Response to Sole Sickle Cell Drug

Published: Friday, February 22, 2013
Last Updated: Friday, February 22, 2013
Bookmark and Share
Only one drug is currently available under FDA regulations, but response varies greatly from patient to patient.

Hydoxyurea is an almost ideal drug for many children with sickle cell anemia. It reduces the severe pain and long-term organ damage caused by sickled blood cells; it can improve lifespan; and it is cheap and fairly safe. And it’s the only FDA-approved medication for sickle cell anemia.

What’s not ideal is the variable response to the drug. “Right now, you just don’t know what’s going to happen when you start a patient on hydroxyurea,” said Nancy Green, MD, associate professor of pediatrics. “Some have only a modest response, while for others, the drug changes the disease, keeps them out of the hospital, and gets them back to their lives.”

“If the drug isn’t going to do much for a patient, we want to know so we can start thinking about other options, blood transfusions or a bone marrow transplant, that are not as easy or readily available.”

Genetic differences among patients undoubtedly play a role. With the help of a consortium she organized—with researchers from Albert Einstein, Weill-Cornell, Yale, Oakland Children’s, and the University of Rochester—Green is now starting to identify genes that eventually may help physicians better predict response to hydroxyurea.

In sickle cell disease, a mutation in the hemoglobin gene causes the hemoglobin molecules inside red blood cells to stick to each other. When that happens, the cells become damaged and lose their flexibility, causing them to assume a sickle shape. If patients also produce enough fetal hemoglobin—normally produced only in very small amounts after birth—more red blood cells retain their normal round shape and flow through the microvasculature throughout the body. Hydroxyurea works in large part because it increases the production of fetal hemoglobin, thereby reducing sickling and its complications.

The amount of fetal hemoglobin patients can produce on their own is often an indication of the degree to which they will respond to the drug, but not always. Many patients with high baseline levels fail to mount a large fetal hemoglobin response to the drug, while fetal hemoglobin sometimes surges even in patients with low baseline levels.

A recent study published by Green and her colleagues in PloS One looked at predictors of hydroxyurea response in 117 children and found that baseline levels of fetal hemoglobin explain 33 percent of the variation in patient response.

That percentage increased to almost 50 percent when the researchers factored in each patient’s type of epsilon globin gene. Green and her team also found other genes that seem to be linked to the fetal hemoglobin response to drug, but those will need to be investigated in future studies with more patients.

“Our genetic results still need to be confirmed by other researchers, and we need to find the factors that control the other 50 percent of the variation in response, but I think we will soon get to a point when we can more reliably predict who will do well on hydroxyurea,” Green said.

“With a prediction tool, we could identify patients who should benefit but aren’t because of difficulty adhering to the daily regimen. And we could offer the drug earlier to those who are most likely to respond,” she said.

“For many children with sickle cell disease, the earlier they start using hydroxyurea, the greater impact it will have on their lives.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DNA Abnormalities Found in Children with Chronic Kidney Disease
Routine genetic screening of children with CKD could lead to earlier, more precise diagnoses.
Tuesday, April 21, 2015
Patient-Specific Stem Cells and Personalized Gene Therapy
Patients’ own cells transformed into model for studying disease and developing potential treatment.
Saturday, July 12, 2014
Global Study Discovers Flurry of New Alzheimer’s Genes
An international study has uncovered 11 new genes that increase the chance of developing Alzheimer’s disease and provide new clues to ways of fighting it.
Wednesday, October 30, 2013
Test Could Identify Which Prostate Cancers Require Treatment
3-gene biomarker gauges tumor’s aggressiveness.
Thursday, September 12, 2013
Columbia Licenses Novel 3-D Organ and Tumor Segmentation Software to Varian Medical Systems
Allows for more precise and efficient planning and monitoring of cancer treatment.
Friday, May 17, 2013
Study Shows Why Leukemia Returns in Some Children
With sophisticated new DNA techniques, a team of researchers has found, for the first time, why many children with a type of leukemia suffer a relapse.
Thursday, February 28, 2013
Two Treatments for Retinitis Pigmentosa Move Closer to Clinical Trials
One treatment involves skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy.
Friday, December 21, 2012
New Prenatal Gene Test Proposed as Standard of Care
Findings Published in NEJM show that microarray finds significantly more clinically relevant information than current method.
Thursday, December 06, 2012
Columbia Awarded One of First NCI “Provocative Questions” Grants
Timothy H. Bestor, PhD, an epigenetics researcher and professor of genetics and development at CUMC, was selected for his proposal, “Methylation Suicide in Cancer”.
Friday, September 21, 2012
DNA Repair: How Chromosomes Find Each Other
Study found that after a double-strand break in DNA, the mobility of both the broken segment and other, unbroken, chromosomes is greatly increased.
Wednesday, June 06, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!